Company intelligence / Profile preview

Lantus Biopharma

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Lantus Biopharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing next-generation small molecule drugs for oncology. The company leverages its proprietary DNA Damage Response (DDR) platform to design highly selective inhibitors targeting key enzymes in DNA repair pathways. Its lead program, LTS-001, is a DNA-PK inhibitor currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors. Lantus Biopharma focuses on both monotherapy and combination strategies to overcome drug resistance and improve patient outcomes in cancer care.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

vesemnogene lantuparvovec

Beyond the preview

Go deeper on Lantus Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lantus Biopharma.

Explore the full profile